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Diabetes is a life- long illness that requires close monitoring. The increasing cost of 
care could hinder access to quality care consequently leading to high morbidity, 
mortality and productive losses. The main objective of this study was to estimate the 
cost of illness of diabetes for patients receiving medical care at Mt. Kenya Sub 
County Hospital, Kenya. The specific objectives were to detennine the direct 
healthcare and non- healthcare cost of diabetes and their impact on health and 
economic well- being on diabetic patients in a level four facility in Nyeri County. 
The study employed a descriptive design. The total direct healthcare costs were 
estimated to be Kshs. 13,261 per month while total direct non- healthcare costs were 
estimated to be Kshs. 3,088 per month, against an average monthly income of Kshs. 
6,498. Due to the high cost of care in relation to income, patients developed coping 
mechanisms such as non- compliance to the recommended lifestyle and consequently 
were at risk of adverse health outcomes. The results of the study will be useful for 
the hospital administration to ensure comprehensive health promotive and preventive 
education on diabetes to patients. For patients and their families, the results of the 
study may be used to lobby for better horne based care, fidelity to treatment and a 
health- promotive regimen and reconsideration of options for payment of health 
services. Finally, for policy makers the results of the study offer an oppmiunity to 
revisit and strengthen policies on diabetes prevention, and financing for non-
communicable diseases in general and diabetes in particular. 
v 
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This chapter presents a background to the study, the research gap, research 
objectives, research questions, rationale and scope of the study. 
1.2 Background of the study 
Diabetes is among the top 10 causes of death globally and accounts for over 80% of 
all premature deaths due to non-communicable diseases together with cardiovascular 
diseases, cancer and respiratory diseases (Murray, 2017). Diabetes mellitus refers to 
a group of chronic, non-communicable, metabolic disorders that manifest as 
hyperglycemia- raised levels of glucose in blood (Fauci et al,2001 ). Diabetes occurs 
when the body catmot produce enough insulin or is unable to utilize insulin. Insulin, 
a hormone produced by the pancreas, is required to drive in glucose from the 
bloodstream to the body's cells to produce energy. There are 4 broad categories of 
this disease: type 1, type 2, gestational and other types of diabetes (IDF, 20 17). 
Type 1 diabetes is characterized by an autoimmune reaction of the body towards 
insulin producing cells of the pancreas which results in a relative or absolute 
deficiency of insulin (Fauci et al , 2001 ). It can occur at any age but most commonly 
affects children and adolescents (Fauci et al, 2001). People with type 1 diabetes 
require daily insulin injections to maintain nonnal gluc~se levels. 
Type 2 diabetes results from failure of the pancreas to produce adequate insulin or 
inability of the body to utilize insulin or both (Fauci et al, 2001 ). It is the most 
common type of diabetes accounting for 85% of all diabetic cases in developed 
counhies and a higher percentage in developing countries (Mwangi & Gitonga, 
2014). It is mostly seen in older adults but is increasingly being diagnosed in 
children, adolescents and younger adults due to rising levels of obesity, poor diet and 
physical inactivity (Fauci et al) . The onset of type 2 diabetes is often slow and 
gradual making the actual time of onset difficult to determine (IDF, 2017). 
Consequently, half to a third of type 2 diabetes cases in the population may be 
undiagnosed because they remain without symptoms for many years (IDF, 2017). 
The cause of type 2 diabetes is strongly linked to obesity and being overweight, 
increasing age, ethnicity and family history (IDF, 2017). Modes of treatment for type 
2 diabetes are adoption of a healthy lifestyle, oral medication and insulin to control 
blood glucose levels (Fauci et al; IDF, 2017). 
Gestational diabetes occurs in women with no prior history of diabetes diagnosed 
with high blood sugar levels during pregnancy (Fauci et a!, 2001 ). These women are 
at risk for adverse pregnancy outcomes such as high blood pressure and a large baby 
which can make normal delivery very difficult and· risky (IDF, 2017). Babies born to 
mothers with gestational diabetes have a higher risk of obesity and developing type 2 
diabetes later in life (IDF, 2017). Other specific types of diabetes such as secondary 
diabetes which results as a complication of other diseases and monogenic diabetes 
which arises from a single genetic mutation, are less common (Fauci et a! , 2001; 
IDF, 2017). The lack, or ineffectiveness of insulin causes a high level of blood 
glucose which over the long tenn causes damage to body organs leading to life-
threatening and/or disabling complications such as cardiovascular diseases, 
neuropathy, nephropathy and eye disease leading to -blindness (International Diabetes 
Federq_tion, 2011). However, if appropriate and timely management of diabetes Is 
achieved, these complications can be delayed or prev·ented. 
Globally, 4 million people aged 20- 79 years were estimated to die from diabetes in 
2017(IDF, 2017). This was higher than the combined number of deaths caused by 
communicable diseases (1.1 million deaths from HIV/AIDS, 1.8 million form 
tuberculosis and 0.4 million from malaria in . .2015)(1DF, 2017). Diabetes alone 
accounted for 10.7% of all- cause deaths among people aged 20-79 years old in 
2017, 46.1% of whom were below the age of 60 (IDF, 2017). An increasing 
prevalence and mortality of diabetes among the economically active negatively 
impacts the economic development of a household. 
Additionally, the majority of people with diabetes live in low and middle income 
countries, in which the greatest increase of new diabetes cases will occur in the next 
17 years (Guariguata et al., 2014). Low income countries are projected to have a 92% 
increase in diabetes prevalence, lower- middle income countries 57%, upper-middle 
income countries 46% and higher income countries 25% (Ezzati, 2008; Whiting, 
Guariguata, Weil, Shaw, 2011). The prevalence of diabetes in the WHO African 
region increased by 129%- from 3.1% in 1980 to 7.1% in 2014- (Atun et al., 2017). 
In developed countries, most people with diabetes are above the age of retirement 
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while in developing countries those most frequently affected are between 35-64 
years, therefore impacting people in their most economically productive years 
(World Health Organization, 2004). 
Diabetes is a costly disease to manage due to its chronic nature and complexity of 
complications that arise from it. Global expenditure by people with diabetes aged 20-
79 years was estimated to be USD 232 billion in 2007 ·and USD 727 billion in 2017 
(IDF, 2017). It is estimated that 75% of this amount is from developing countries 
because of urbanization and rapid cultural and social changes (Zhang et al., 201 0). 
Moreover, the healthcare cost of diabetes for a patient varies widely between 
countries e.g. USD 11 ,638 in the United States, USD 87 in Madagascar and USD 44 
in the Central African Republic per year (IDF, 2017). Indeed, every year, more than 
150 million people or approximately 44 million households worldwide face financial 
catastrophe and 100 million people are pushed into poverty as a direct result of 
paying for healthcare (Mylena, Carrin, Evans,-& Xu, 2005). This could be worse for 
p_eople living with diabetes in Kenya who receive frequent treatment paid ·out of 
pocket coupled with increased healthcare costs. The cost of managing diabetes 
includes direct costs incurred in managing the disease and indirect costs due to loss 
of productivity brought on by premature mortality, disability and time spent seeking 
care at healthcare facilities (World Health Organization, 2016). People living with 
diabetes have more outpatient visits, use more medications, have a higher chance of 
being hospitalized and are more likely to require emergency treatment and long- tenn 
care than people without the disease (Kirigia, Sambo, Sambo, & Barry, 2009b ). 
People living with diabetes in Kenya are at a high risk for high economic burden and 
catastrophic expenditure. Catastrophic health expenditure occurs when three factors 
are present: healthcare cost paid out- of- pocket, low household capacity to pay and 
lack of pre- payment mechanisms to pool financial risks (Mylena et al., 2005). When 
·this expenditure is too high in relation to income, households are forced to cut down 
expenses on basic needs such as food and clothing and are unable to cater for their 
children' s education (Mylena et al., 2005). Many people may decide not to use 
healthcare services simply because they are unable to cater for the direct costs such 
as consultation costs, cost of drugs and laboratory tests, or the indirect costs such as 
transport or recommended special diet. This may lead to adverse effects of illness 
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which have the potential of sinking poor households further into poverty (Mylena et 
al., 2005). 
1.3 Burden of Diabetes in Kenya 
Prevalence of diabetes in Kenya was 3.3% in the year 2000 and was projected to rise 
to 4.5% by the year 2025 (Maina et al. , 2010) (J. Brown, 2008). There is however a 
disparity in distribution as the prevalence among urban dwellers is approximately 
10.7% and 2.7% among rural dwellers (Amin et al., 2015). The National Diabetes 
Strategy states that these figures are an underestimate because about 60% of the 
population with diabetes are undiagnosed and present to health facilities with 
unrelated complaints (Maina et al., 2010). It is also estimated that 14% of the Kenyan 
population have impaired glucose tolerance, which is a precursor for developing 
diabetes (Amin et al., 20 15). 
Non- communicable diseases represent at} increasing burden of ill health and death in 
the country (Ministry of Health, 2014). They accounted for 50-70% of_:~ill hospital 
admissions and up to half of all in- patie1_1t mortality in the year 2010 (Ministry of 
Health, 2014). Despite successes in controlling communicable diseases, the -national 
health status has stagnated largely due to the increase of non- communicable diseases 
(World Health Organization, 2019) (Wake et al., 2006). Currently, there is lack of 
population based data on the burden and trends of diabetes and lack of 
comprehensive research that can inform policy on the best practices for the control of 
diabetes (Maina et al., 2010). However, in 2015 a STEPwise survey was conducted 
in the country to provide baseline data on prevalence of non- communicable diseases 
(Arnin et al., 2015). It revealed that while 41% of the population with diabetes had 
been diagnosed, effective treatment coverage was only 7% (Amin et al., 2015). 
Most people with diabetes do not die as a result of causes uniquely related to diabetes 
but of associated cardiovascular complications such as heart attack and stroke (World 
Health Organization, 2014 ). Diabetes was the 9th leading cause of death in Kenya in 
2017, 14th in 2007 representing a 31.2% rise (IHME, 2019). It ranked 4th among non-
communicable diseases namely: ischemic heart disease, stroke and cinhosis that 
caused the highest mortality among persons of all ages (IHME, 2019). In 2017, 
diabetes ranked i 11 among medical conditions that cause the most disability, a 51.7% 
rise from 2007 where it ranked 11th (IHME, 2019). Diabetes poses a risk of 
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development of cardiovascular complications such as stroke ischaemic heart disease 
which respectively were the ih and 8111 leading causes of highest mortality and 
morbidity combined (IHME, 2019) 
Nyeri County is located in the central region of Kenya and has a population of about 
693,558 people as of the year 2009 (KNBS, 2018)It comprises six sub counties, 
namely: Nyeri Town, Mukurwe-ini, Othaya, Mathira, Kieni and Tetu (KNBS, 2013). 
There are four level four hospitals in the county, namely: Karatina, Othaya, 
Mukurwe-ini , Mt. Kenya and one level five hospital, Nyeri County Referral 
(NyeriCounty, 2018). Nyeri County is considered as having the highest sub- national 
prevalence of diabetes which stands at 11.6% and as high as 20% among the richer 
families in the major urban centers (Masemiano, 201 0). 
1.4 Problem Statement 
Diabetes has created a global pro_blem due to the rising. number of cases and 
complications associated with the disease. Four broad reasons exp_lain the rise of 
lifestyle diseases in Africa (of whic~ diabetes may be considered one): unplanned 
urbanization, little understanding of the risks that are associated with chronic disease, 
lack of access to healthcare and cost of treatment (Kirigia, Samba, Samba, & Barry, 
2009a). Diabetes exerts a heavy burden on society in terms of health system costs 
incurred by society in managing the disease, indirect costs as a result of loss of 
productivity due to patient morbidity and premature mortality (Kirigia et al., 2009a). 
Moreover, the proportion of Kenyans living on less than the intemational poverty 
line (USD 1.90 per day in 2011 purchasing power parity) was 35.6% in 2015/6 (The 
World Bank, 2018). For this group, meeting healthcare costs is likely to be a 
challenge. Additionally, health insurance coverage in Kenya is low, with only 17.1% 
of households reported to be in some fonn of pre-payment health scheme (KDHS, 
2014). Indeed, health insurance coverage among the lowest wealth quintile was 3% 
compared to 42% in the highest income quintile in 2014 (KDHS, 2014). About 
88.4% of households with health insurance are covered through NHIF, the other 
11.6% through private health insurance (Mwai, 2017). Finally, on health financing, 
the national total health expenditure was Kshs346 billion in the financial year 
2015/6, of which 26.1% was through household out-of-pocket payments (Mwai, 
2017). Kenya does not have adequate funds for diabetes prevention or care. Kenyans 
5 
who can, independently fund their care- which places them and their families at a 
risk of pove1iy and poorer health should they not have adequate funds to finance 
chronic ailments such as diabetes. Some save money through non- compliance, 
increasing the risk of complications (Wake et al., 2006). 
The lack of comprehensive research on diabetes cost of illness from a patient/ family 
perspective makes it hard for policy makers to realize the need to chmmel more effort 
towards diabetes prevention and emphasis on enrollment in pre- payment 
mechanisms to cushion families against out- of- pocket payments. Consequently, to 
address this gap, this study seeks to assess the cost faced by patients and their 
families in managing diabetes. The geographic area of study will be Nye1i County 
that has been determined as having the highest sub- national prevalence of the 
disease. 
1.5 Research Objectives 
1.5.1 Main Objective 
The broad objective was to dete.rmine the cost of diabetes among patients at a level 
four healthcare facility in Nyeri Town Sub County. 
1.5.2 Specific Objectives 
1. To estimate the direct costs borne by patients in addressing diabetes at a level 
four facility in Nyeri Town Sub County. 
11. To determine the impact of direct costs of diabetes on the health and 
economic well- being of patients at a level four facility in Nye1i Town Sub 
County. 
1.6 Research Question 
The study sought to answer the following questions: 
1. What is the direct cost of diabetes for patients at a level four facility in Nyeri 
Town Sub County? 
u . What is the impact of cost on the health and economic well- being of diabetes 
patients attending at a level four facility in Nyeri Town Sub County? 
1. 7 Rationale of the study 
Given the increasing burden of diabetes in tenns of prevalence, morbidity and 
mortality, this study estimated the cost of illness among diabetes patients in Nyeri 
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Town Sub County at a level four facility, namely_ the Mt. Kenya Sub County 
Hospital, which will be of importance to several key players. 
The study challenges Mt. Kenya Sub County Hospital to introduce screening 
programs and provide comprehensive patient education on diabetes and its 
complications. This will help in early diagnosis of diabetes and consequently prevent 
or delay the onset of complications. Additionally, patient education will hopefully 
challenge the population to adopt healthier lifestyles to prevent diabetes onset. 
This study will also hopefully inspire introduction of more robust programs at the 
Nyeri County Govemment policy level to reduce the incidence of diabetes in the 
county which may be replicated country wide. 
1.8 Scope of the study 
This study was limited geographically to Mt. Kenya Sub County Hospital thereby 
leaving out the other hea1th facilities in the county.· The respondents of the study 
were patients living with diabetes for up to five years and attending diabetes 
outpatient clinic at the facility. Chronic illnesses in Kenya are mostly managed at 
tertiary healthcare facilities which are mostly owned by government. Patients with 
advanced disease and complications are mostly managed at the Nyeri County 
Referral Hospital, while the rest are managed at level four facilities . The study was 
limited to determining the cost of managing diabetes among patients attending 
diabetes outpatient clini'c at the level four hospital. 
1.9 Limitations 
To circumvent the possibility of respondents not gtvmg infonnation freely, any 
personal information was anonymized, respondents were presented with a signed 
confidentiality agreement and were continually assured that their information would 
be treated with utmost confidentiality. I also highlight that due the one year recall, 
some cost items were missed due to forgetfulness. Furthermore, self-report of costs 
may give an underestimation or exaggeration of the problem. Access to multiple 
points of care within the period of study also complicated my ability to detennine all 





This chapter presents a background of the literature review, an overview of cost of 
illness studies, a review of published articles and the conceptual framework 
2.2 Background 
The burden of diabetes, cardiovascular diseases and related risk factors is rapidly 
growing in Africa and the group mostly affected is young adults and especially those 
in the lower socio-economic strata. Moreover, African health systems are not strong 
enough to cope with the existing double burden of communicable and non-
communicable diseases (Kengne~ McHiza, Amoah, & Mbanya, 2013). Given_ the 
double burden of disease and limited resources, ·diabetes must compete for political 
--
attention and financial investment. In previous centuries, non- communicable 
diseases were referred to as 'prosperity diseases ', in th~t they were a reserve for the 
rich and elite in society. The majority of the population at the time lived in rural set-
ups and languished in poverty and diseases such as diabetes were largely unheard of 
in Africa (Jakovljevic & Milovanovic, 2015). However, the adoption of new 
lifestyles and dietary practices coupled with epidemiological transition and 
demographic changes have led to a rapid increase in the number of individuals with 
diabetes in Africa (Azevedo & Alla, 2008). It was estimated that in 2017, five 
million deaths worldwide were attributed to diabetes in persons aged 20-99 years 
(Cho et al., 2018). Over a third of these deaths (1.8 million or 36.5%) occurred in 
people under the age of 60 years. The largest proportion of deaths attributed to 
diabetes in those below the age of60 was in the African region at 73.7% (Cho et al., 
2018). The International Diabetes Federation (IDF) estimated that 15.5 million adults 
aged 20-79 years had diabetes in 2017 in Africa and the number is expected to tise to 
40.7 million adults aged 20-79 years by 2045 (IDF, 2017). 
In 2017, USD 3.3 billion was spent on healthcare by people with diabetes in Afiica. 
This amount is projected to reach USD 6 billion by the year 2045 (IDF, 2017). These 
figures are however an under-estimate because about 69.2% of adults aged 20-79 
years living with diabetes are undiagnosed. This unmet need for diabetes diagnosis is 
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due to weak health systems that fail to screen the population for diabetes (Manne-
Goehler & A tun, 20 16). Individuals with diabetes are risk of developing chronic 
complications such as hemi disease, eye complications and kidney disease (IDF, 
2017). These complications, in addition to the rise in diabetes prevalence will make it 
a very expensive disease to manage. 
The increase in diabetes prevalence and mortality places a strain on the already over-
stretched African health systems. The need to address the non- communicable 
disease pandemic is now enshrined in the 17 Sustainable Development Goals. The 
target of SDG 3 is to reduce by one third, premature m01iality from non-
communicable diseases through prevention and treatment by the year 2030 (UN, 
20 19). The successful accomplishment of this goal will lead to a decrease in 
prevalence of non- communicable diseases and consequently a reduction in the cost 
of managing the condition. 
In response to the increasing burden of non- c:s>mmunicable diseases, in 2015 the 
government of ~enya launched a five year National Strategy for the Prevention and 
Control of Non- communicable Diseases (M.o.H., 2015). Similarly, a five year 
National Diabetes Strategy was launched in 2010 (Maina et al., 2010).The common 
goal of these strategies is to guide the implementation of interventions to reduce the 
morbidity and mortality due to non- communicable diseases. 
Cost of illness studies have been used in conducting research on a wide array of 
diseases and continue to inform on economic evaluations of treatments and other 
healthcare interventions despite the fact that their usefulness has been questioned 
(Rice, 2000). An assessment of diabetes cost in Kenya is of importance because the 
disease incidence is on a rapid increase and mostly affects young people thus has the 
potential to affect economic productivity and threaten the lives of many families. An 
estimation of costs attributed to diabetes can give insight on importance of diabetes 
prevention and facilitate adoption of cost- effective treatment options 
2.3 Overview of cost-of-illness studies 
2.3.1 Definition of costs 
Cost of illness studies (COl) classify costs into three categories: direct costs, indirect 
costs and intangible costs. 
9 
Direct costs 
Direct costs are the resources used to treat the disease, that is, expenditure for 
medical care and treatment (Segel, 2006; Jo, 2014). Direct costs has two sub-
categories: a) direct medical costs which include hospitalization costs, medication, 
laboratory tests, emergency services, medical supplies, outpatient visits and 
traditional medicine services; and b) direct non- medical costs which include 
transport cost to health facility and cost of meals en- route to hospital (Segel , 2006; 
Jo, 2014). 
Indirect costs 
Indirect cost refers to the productivity losses due morbidity, disability or premature 
mortality borne by the individual, family society or by the employer (Segel, 2006; Jo, 
2014). There are three methods of measuring indirect costs: 
Human capital method: The productivit_y losses associated with the morbidity and 
mortality of an individual are the market value of that individual ' s future 
contribution in society if s/he had continued to work in full health (Jo, 2014). 
Thus, the human capital method (HCM) is designed to estimate the value of 
human capital as the present value of his/ her future earnings under the 
assumption that we use future earnings as a proxy for future productivity(Jo, 
2014). 
Friction cost method: The friction cost method (FCM) estimates the value of 
human capital when a person from the unemployment pool replaces the present 
value of a worker's future earnings until the sick worker returns or is eventually 
replaced (Jo, 2014). Hence, the friction cost (initial disruption costs plus training 
costs) is limited to the illness or death over a shmi- term period defined as 
'friction period' (Jo, 2014). 
Willingness to pay method: The willingness to pay method (WTP) measures the 
amount that an individual is willing to pay in order to reduce the probability of 
illness or mortality (Jo, 2014). 
Intangible costs 
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These costs cannot be conve1ied to money and are immeasurable (Segel, 2006). They 
include social and emotional costs like pain, suffering, and lack of quality of life, 
lack of participation in social events or poor emotional health (Segel, 2006). 
2.3.2 Perspective of COl studies 
The perspectives used are societal (loss if income while canng for the sick), 
pmiicipants and their families (for example out- of- pocket payments), healthcare 
system, third- party payers, business sector (loss of productivity) and the govemment 
(infrastructure, support program costs (Jo, 2014)) . Each of these categories include 
marginally different sets of cost of items and thus each perspective gives rise to 
different kinds of results for the same disease (Hodgson, 1994; Segel, 2006). Table 1 
presents the cost categories included in each perspective. The societal perspective is 
the most comprehensive because it includes all direct medical costs and indirect costs 
for all members in each society where they are all involved. It however requires the 
largest sizeable data making it difficult to use in specific cases with less prevalent 
diseases. In the business perspective, ffie friction method is dominant (J o, 2014 ). 
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Table 1. 1: Costs included in cost- of- illness studies by perspective 
Perspective Medical Morbidity Mmiality Transportation 
Societal 
Healthcare system 








































Source: Luce & Manning, 1996 (Luce & Manning, 1996) 
2.3.3 Approaches to COl studies 














The approach of a COl study can either be prospective or retrospective (Jo, 2014). 
For a prospective approach, all relevant cost components are followed up over a 
certain period of time in the future (Jo, 2014). This makes this approach expensive in 
terms of time and resources. In a retrospective approach, all relevant cost 
components are followed up from previous records. It is thus less time consuming 
and less expensive (Jo, 2014). 
Prevalence vs. incidence approaches 
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Common epidemiological approaches in COl are prevalence based and incidence 
based approaches (Segel, 2006 ; Jo, 2014). The prevalence approach is used to 
estimate the economic burden of a disease over a specified length of time, commonly 
six months to a year (Segel, 2006; Jo, 2014). The incidence approach involves 
analysis of cost of a case within a given pe1iod and usually follows people at similar 
stages of disease or diagnosis. It estimates the life- time cost of a condition from its 
onset until its disappearance (cure or death). The prevalence- based approach is the 
most practicable method to measure the nature of long- lasting conditions that 
require considerable lengthy follow- up petiods. Both prevalence- based and 
incidence- based COl studies can be organized either in a prospective or 
retrospective way (Tarricone, 2006). 
Top- down vs. Bottom- up vs. Econometric approaches 
1) Top-down approach: The top-down approach, also referred to as the 
epidemiological or __ attributable risk approach measures the propmiion of a 
disease that is attributable to exposure to the disease or risk factors (J o, 2014) 
2) Bottom- up approach: In bottom- up approach, the estimation of costs is 
stratified into two steps. The first step is to measure and quantify the health 
inputs used and the second step is to estimate the unit cots if the inputs used 
to produce and confer specific medical and healthcare services. The total cost 
is a result of the multiplication of the unit cost and units used (Jo, 2014) 
3) Econometric approach: The econometric approach tries to estimate the 
difference in cost between a cohort with the disease and another cohort 
without the disease (Jo, 2014). 
Consequently, and based on the attributes discussed above, this study takes on a 
bottom- up, retrospective, prevalence-based approach. 
2.3.4 Defining the disease and population 
Most of the studies focused on the cost of diabetes type 2, five focused on both type 
1 and 2, six did not specify on the type of diabetes while none considered the cost of 
type 1 diabetes in isolation. 75% of the studies focused on general costs of diabetes, 
10% on cost of drugs while the remaining 15% focused on cost of the diabetic 
complication of foot ulcer. In addition to discussing the general costs of diabetes, 
three studies also estimated the costs of diabetes complications such as hypetiension, 
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stroke and nephropathy (Alouki et al. , 2015; Suleiman & Festus, 2014; Mutowo et 
al., 20 16). Most studies included had sample sizes ranging from 101-1000 (n=8), 
followed by 0-100 (n=5). Two studies had sample sizes of over one million and five 
studies were hypothetical and costs were calculated without utilizing any samples 
(Alouki et al., 2015; Lamlili, & Boutayeb, 2013 ; Cavanagh, Attinger, Bal, Roj as, & 
Xu, 2012; Jingi et al. , 2014; Subramanian et al. , 2018). In selecting the samples to be 
included in the studies, five specified the age of the individuals (Basu, Shankar, & 
Yudkin, 2017; Eliadarous et al. , 2010; Fadare, Olamoyegun, & Gbadegesin, 2015; 
Okediji et al. , 2017; Okoronkwo, Ekpemiro, Okwor, Okpala, & Adeyemo, 2015) and 
two studies specified the duration of illness (Eliadarous et al. , 201 0; Okediji et al., 
2017). 
This study will focus on the general cost of both type 1 and 2 diabetes of a total of 
sixty patients. 
2.3.5 Epidemiologic~! Approach 
Only one study used the incidence approach whereby a life course of new and 
present diabetes cases was simulated over the period of 2016-2025 (Basu et al. , 
2017). The others studies utilized the prevalence approach where they estimated the 
economic impact of existing diabetes cases over a period of one month to two years. 
This study will utilize the prevalence approach where the cost of diabetes from 151 
November 2017 to 301h November 2018 will be estimated. 
2.3.6 Study perspective 
The most commonly utilized perspective was the patient perspective, followed by the 
societal perspective then combined patient and health system perspective. Some 
studies did not specify the perspective, but the reviewer was able to interpret and 
classify them. This study will utilize the patient perspective. 
2.3.7 Data resources 
A majority of the studies reviewed used hospitals/ medical centers as their sources of 
data, some studies conducted patient interviews while others studies employed 
various sources such as healthcare providers and suppliers catalogues, intemational 
drug price indicators, non-governmental organizations and health insurance data. 
This study will use patient interviews and hospital data records 
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2.3.8 Resource quantification 
Resource consumption can either be estimated prospectively or retrospectively 
(Tarricone, 2006). Prospective cost of illness studies require one to follow up 
patients over time while in retrospective studies the relevant costs are retrieved from 
previous records. Two studies estimated costs prospectively (Basu et al. , 2017; 
Pepper, Burch, Levitt, & Cleary, 2014), two studies were hypothetical(Cavanagh et 
al. , 2012; Basu et al., 2017) and the rest employed a retrospective approach. Sixteen 
studies used the bottom- up approach in which either patient interviews were 
conducted (Eliadarous et al., 201 0; Fadare et a!., 2015; Okediji et a!., 2017; 
Okoronkwo et al. , 2015; Bennudez-tamayo, Johri, & Assa, 2017; Mwavua, Ndungu, 
Mutai, & Joshi, 2016) or hospital/ health centre records were reviewed (Alouki et al. , 
2015; Suleiman & Festus, 2014; Mutowo et al., 2020; Cavanagh eta!., 2012; Jingi et . 
al., 2014; Subramanian et al., 2018; Pepper et al. , 2014; Danmusa, Terhile, Nasir, 
Ahmad, & Muhammad, 2016; Ipingbemi & Erhun, 2015; Quaye, Amporful, 
Akweongo, & A!!<:ins, 2015) to gather activity data. One study used the econometric 
approach whereby direct and indirect costs between diabetic and non- diabetic · 
patients were compared (Bennudez-tamayo et al., 2017). Expeti opinion or standard 
practice was used to estimate cost of illness in tow studies (Basu et al., 2017; 
Volmink, Bertram, Jina, Wade, & Hofinan, 2014). Resource consumption was 
estimated using various national indicators, national surveys and published studies in 
two studies (Kirigia et al., 2009a; Boutayeb et al., 2013). One study estimated 
resource consumption based on price data form tenders from the ministries of health 
at the point of entry to the given countries (Atun et al., 2017). 
2.3.9 Cost of diabetes mellitus 
There has been growing concern over the increase in prevalence of diabetes in Africa 
and a growing need for the need to address the burden associated with the disease by 
prioritizing interventions that prevent or delay the onset of the illness. For this to be. 
achieved, in depth knowledge on the cost of managing the illness needs to be realized 
in order to grasp the magnitude of the problem on society. 
All the studies reviewed provided sufficient information to calculate the per capita 
costs of diabetes and two studies extended the national cost of diabetes (Suleiman & 
Festus, 2014; Boutayeb et al., 2013). The per capita direct cost of diabetes in 
Morocco in 2013 was estimated to be between USD 259 and USD 830 per year 
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which represented a 1.75 to 5.6 times the per capita health expenditure (USD 148) 
(Boutayeb et al., 2013). Indirect cost per capita was USD 1113 per year .. Indirect 
costs accounted for 57% to 81% of the total economic cost of diabetes in Morocco. 
The study found a large variability in the costs related to treatment of diabetes 
between NGOs, government and private health sectors. To overcome this, three 
scenarios were used: high, low and medium price. Prevalence of diabetes was based 
on values provided by the Intemational Diabetes Federation, World Health 
Organization and the Moroccan ministry of health. Indirect costs were estimated 
using the human capital method whereby the lifetime foregone eamings caused by 
premature death and disability due to diabetes are calculated. The study estimated all 
the costs from as patient perspective. Boutayeb and colleagues (2013) recommend 
that given the economic and sustainable development issue caused by diabetes, 
health decision makers should consider diabetes in its integrated context, requiring 
health education and sensitization, early diagnosis and treatment avoid complications 
or at least d~lay them as far as possible. 
2.4 Conceptual framework 
The figure below presents a conceptual framework of the cost of illness of diabetes. 
The figure illustrates the various components of cost related to diabetes. Various 
approaches can be used to determine the economic burden of a public health problem 
. such as diabetes. These include: the willingness- to- pay approach (Kirigia, Sambo, 
& Kainyu, 2000), the macroeconomic/ production function approach (Kirigia, 
Sambo, Aldis, & Mwabu, 2004) and the cost-of- illness approach (Kirigia & Sambo, 
2003). This study employed the latter approach because it highlights the magnitude 
of the impact of an illness on a society. Due to the complexity in determining indirect 
costs of illness, this study will focus on the direct costs only. 
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This chapter presents the research design used, target population, sampling method 
and size, inclusion and exclusion criteria, data analysis, research quality and ethical 
issues faced in the research. 
3.2 Research design 
This was a descriptive study. This design is appropriate for this kind of study that 
attempts to retrospectively detennine costs incmTed over a period of time and results 
in credible infonnation (Ruspini, 2002). Data was collected through patient 
interviews and through reviews of secondary data- most notably, patient files. 
3.3 Target population 
}\~spondents in the study were patients living with diabetes for the last five years and 
who attended diabetic outpatient clinics between January 2018 and November 2018. 
The ·period was limited to one year due to the limitation in recall of infonnation by 
respondents. The month of December was also excluded from the study because 
since the Universal Health Coverage (U-H-C) programme was launched in that 
month, patients in Nyeri County have been accessing health services free of charge 
in all government facilities. Patients living with diabetes for more than five years 
were excluded from the study due to the higher prevalence of diabetes- related 
complications and co- morbidities which may not give a true picture of cost of 
diabetes management in isolation. 
3.4 Sampling and samples size 
A total of 921 diabetes outpatient clinic visits were made between the month of 
January 2018 and November 2018, with an average of 83.7 visits. Using this average, 
a sample size of 83 patients who satisfied the inclusion criteria was selected 
randomly. 
3.5 Inclusion Criteria 
Patients living with diabetes for up to five years and attended diabetes outpatient 
clinic between January 2018 and November 2018. 
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3.6 Exclusion Criteria 
a. All patients who decline consent and patients under the age of 18 without a 
parent/guardian with them at the time of the study. 
b. Patients who cannot be traced at the time of study. 
c. Patients who have lived with diabetes for more than five years. 
d. Patients who have not attended diabetes outpatient clinic between January 
2018 and November 2018. 
3.7 Data collection methods 
Primary and secondary data will be collected in this study. P1imary data was 
collected using a structured questionnaire, while secondary data was collected from 
patient files. Data collected from questionnaires comprised of consultation cost, 
hospitalization cost, cost of health insurance, cost of transport arid cost of hiring an 
extra caregiver. The patient files were used to collect data on type of diabetes, 
comorbidities, types and quantity of medication used, laboratory and radiological 
tests done: The unit costs of drugs and tests was sought from the_ hospital software-
medboss. The cost of drugs and tests was obtained by multiplying the unit costs by 
the number of the respective commodities. 
3.8 Data Analysis 
After questionnaires were collected, they were checked for completeness and 
accuracy. Only complete and accurately filled questionnaires were considered for the 
study. Data from the questionnaires was analyzed using excel. Descriptive statistical 
tools such as mean and frequency were adopted. Cross tabulation using excel was 
used to establish the relationship between certain characteristics of the respondents. 
3.9 Research Quality 
3.9.1 Validity 
Validity detennines whether the research truly measures that which it was intended 
to measure (Golafshani, 2003). Tools that researchers use are valid if their contents 
are relevant to the study's objectives. Consequently, experts reviewed the 
questionnaire to establish both face and construct validity. 
3.9.2 Reliability 
Reliability is the extent to which the results of a study are consistent over time, are an 
accurate representation of a population and can yield the same results on repeated 
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trials (Golafshani, 2003). First, the researcher structured questions m the survey 
following those used in prior studies that have been tested and validated. Second, the 
researcher pretested questionnaires with five patients, who did not participate in the 
main study. The researcher then evaluated the completed research instruments to test 
for reliability following which the revised tools were applied to the main study. 
3.10 Ethical Issues in Research 
Ethical considerations regarding the research process were dealt with by obtaining 
ethical clearance to legitimize the study from the Ethics Review Committee and the 
Nyeri County Govemment. Informed consent was sought from all respondents and 
their responses held in confidence. For the respondents under the age of eighteen, 
informed consent was obtained from the parent or guardian. Dming the study, the 
researcher followed ethical guidelines to ensure that no participant faced physical, 
psychological or emotional hann. Ethical considerations regarding the researcher 




PRESENTATION OF RESEARCH FINDINGS 
4.1 Introduction 
This chapter presents data findings from the field, its analysis and interpretation 
thereof. The data was collected through patient interviews, infonnation from the 
patients ' files and price data list from the hospital. The data findings were on the cost 
of diabetes disease among patients at a level four facility in Nyeri town Sub County. 
There was a 100% response rate which was achieved after the researcher explained 
the nature and purpose of the study to the interviewees. 
4.2 Demographic characteristics 
The study examined the background infonnation of the respondents regarding age, 
gender, marital status, education level and work status. The results are discussed 
below. 
4.2.1 Age category 
Table 4. 1: Distribution of respondents by age category 
Age Frequency Percentage 
18-25 2 2.5 
26-35 4 4.8 
36-45 9 10.8 
46-55 16 19.3 
56-65 20 24.1 
66-75 25 30.1 
Over 75 7 8.4 
Total 83 100 
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The results of age distribution shows that majority of the respondents attending 
diabetes outpatient clinic at Mt. Kenya Sub County Hospital are in the 66-75 years 
age bracket, followed by those in the 56-65 years age bracket. 73.5% of the 
respondents are between the ages 46-75. This is the category of patients more likely 
to develop diabetes in the population. 
4.2.2 Gender 
The distribution of the respondents according to gender is shown in the table below 













Results from the respondents sampled indicated that the majority were female at 
61.4% whereas male comp1ised of 3 8.6%. 
4.2.3 Marital Status 
Table 4. 3: Distribution of respondents as per marital status 
Marital Status Frequency Percentage 
Married 40 48.2 
Single 10 12 
Divorced/ separated 12 14.5 
Widow/ widower 21 25.3 
Total 83 100 
From the findings, 48.2% of the respondents were married, 25.3% widowed, 14.5% 
were separated/ divorced and 12% were single. 
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4.2.4 Education level 
Table 4. 4: Distribution of education level of the respondents 
Highest education level Frequency Percentage 
attained 
No formal education 18 21.7 
Primary 27 32.5 
Secondary 29 35 
University/college/ 8 9.6 
polytechnic 
Postgraduate 1 1.2 
Total 83 100 
From the findings, 35% of the respondents had attained secondary education, 32.5% 
primary education, 21.7% had no fmmal education, and 9.6% had reached university 
I college I polytechnic level while 1.2% had attained postgraduate level. This is 
representative of the results by the Kenya National Bureau of Statistics which in 
2013 estimated that 34% of Nyeri County residents had a secondary level of 
education and above, 54% had primary level of education only and 12% had no 
fonnal education (KNBS, 2013). 
4.2.5 Work Status 
Table 4. 5: Work status 













At the time of study, 61.4% of the respondents were unemployed and 38.6% were 
employed. 
4.2.6 Source of Income for the Unemployed 
Table 4. 6: Source of income for the unemployed 
Source of income Frequency 
Suppmi from family members 3 
Pension 9 
Fanning 15 









46.9% of the unemployed eamed income from selling their fann produce, 28.1 % 
were retired and relied on pension, 15.6% relied on income from other businesses 
other than farming while 9.4% wholly depended on family members for upkeep. 
4.2.7 Active Health Insurance enrollment 









69.9% of the respondents were not actively enrolled in any health insurance scheme, 
30.1% were enrolled. 
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4.2.8 Hiring of an extra housekeeper 












80.7% of the respondents did not require hiring an extra housekeeper while 19.3% 
did. 
4.3 Descriptive findings 
This section presents findings in accordance to the objectives of the study. 
4.3.~ Duration of illness 
Table 4. 9: Duration of illness 
Duration of illness in years Frequency Percentage 
1 17 20.5 
2 22 26.5 
3 13 15.7 
4 25 30.1 
5 6 7.2 
Total 83 100 
30.1% of the respondents had lived with diabetes for four years, 26.5% for two years, 
20.5% for one year, 15.7% for three years and 72% for five years. 
25 
4.3.2 Type of diabetes 









95.2% of the respondents had type two diabetes and 48%had type one diabetes. This 
infonnation was sourced from their files. 
4.3.3 Number of years attending clinic 









63.9% of the respondents had been attending diabetes outpatient clinic for three to 
five years and 36.1% for zero to two years. 
4.3.4 Frequency of attendance between January 2018 and November 2018 
Table 4. 12: Frequency of clinic attendance 
No. ofvisits Frequency Percentage 
1-5 72 86.7 
6-10 11 13.3 
11-15 0 0 
Total 83 100 
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86.7% of the respondents had attended diabetes outpatient clinic between one to five 
times over the study period of January 2018 and November 2018 and 13.3% had six 
to ten visits. 
4.3.5 Co- morbidities 











Majority of the respondents had hypertension as a co- morbidity, followed by 
arihritis and COPD. Some respondents had more than one comorbidity. This 
infonnation was obtained from their medical files. 
4.3.6 Cross tabulation of type of drugs used and average cost per month 
. , 
Table 4. 14: Cross tabulation of type of drugs used and average cost per month 
Drug 
Oral drugs only 
Insulin only 




















The majmity of respondents, 63.8% were on oral diabetes drugs only, 22.9% were on 
both oral drugs and insulin while 13 .3% were on insulin only. This data was obtained 
from the respondents' files . Patients who were on both insulin and oral drugs spent 
the highest amount on drugs per month, Kshs. 948 while patients on oral drugs only 
spent the least amount, Kshs. 474. Patients on insulin only spent Kshs. 673. 
4.3.7 Hospitalization between January 2018 and November 2018 












84.3% of the respoi1dents had not been hospitalized between January and November 
2018, 15.3% had been hospitalized at least once due to diabetes. 
4.3.8 Reasons for hospitalization 















Of the respondents who had been hospitalized, 61.5% were due to hyperglycemia, 
15.4% due to respiratory illnesses and 23 .1% due to other illnesses. 
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4.3.9 Cross tabulation of adherence to diabetes- specific diet and total direct cost 
per month 
Table 4. 17: Cross tabulation of adherence to diabetes- specific diet and total direct 
cost per month 
Frequency Percentage Total direct cost 
per month 
(Kshs.) 
Yes 27 32.5 15,649 
No 56 67.5 17, 836 
Total 83 100 33,485 
67.5% of the respondents did not adhere to a diabetes- specific diet and spent Kshs. 
17, 836 per month on healthcare. 32.5% adhered to a diabetes specific diet and spent 
Kshs. 15,649 per month on seeking healthcare. 
4.3.10 Reasons for not being on diabetes- specific diet 
Table 4. 18: Reasons for not being on diabetes- specific diet 
Reasons Frequency 
Financial constraints 29 
Lack ofknowledge 12 









Ofthe 56 respondents who did not adhere to a diabetes-specific diet, 51.8% cited 
financial constraints as the reason, 21.4% reported they had no knowledge on such a 
diet, 17.9% had the knowledge but chose to not comply while 8.92% had a wide 
variety of reasons as to why they did not adhere to a diabetes- specific diet. 
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4.3.11 Direct Healthcare Costs 
Table 4. 19: Direct Healthcare costs per capita per month 
Healthcare costs Average cost in Percentage of total 
Kshs 
Oral drugs 306 2.3 n= 53 
Insulin and syringes 550 4.1 n=11 
Consultation 132 1 n= 58 
Cost of 6,783 51.1 n= 13 
hospitalization 
Cost of laboratory 2,610 19.7 n= 69 
tests 
Cost ofradiological 2,380 18. n= 12 
tests 
Cost of insurance 500 3.8 n= 58 
premmm 
Total 13,261 ., 100 
The total direct healthcare cost was Kshs. 13,261 per capita per month. The cost of 
hospitalization accounted for the largest share of this cost, at 51 .1 %, followed by 
laboratory tests at 19. 7%, radiological tests at 18%, insulin and syringes 4.1 %, 
insurance premium 3.8%, oral drugs 2.3% and lastly consultation 1%. 
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4.3.12 Direct non- healthcare costs 
Table 4. 20: Direct non- healthcare costs per capita per month 
Non- healthcare Average cost in Percentage oftotal 
costs Kshs. 
Transpmi 564 18.3 n= 83 
Changes in diet 1,250 40.5 n= 43 
Extra housekeeper 1,274 41.2 n= 16 
Total 3,088 100 
The total direct non- health care cost was Kshs. 3,088 per capita per month. 41.2% of 
this amount was spent on hiring of an extra housekeeper, 40.5% on cost of making 
changes to diet and transport comprised 18.3% 
4.3.13 Total Direct cost 
The total direct cost was obtained by adding total direct healthcare costs to total 
direct non- healthcare costs: 
Total direct cost= Total direct healthcare cost+ total non- healthcare direct cost 
=13 ,261+3, 088 
= Kshs. 16,349 
Kshs. 16,349 was the total direct cost incurred per capita per month. Direct 
healthcare costs comprised 81.1% of this amount while direct non- healthcare costs 




Diabetes exerts a heavy economic burden on individuals. Consequently, they need 
comprehensive healthcare insurance coverage to cushion them against catastrophic 
health expenditure. Majority of the respondents in this study, 69.9% did not have 
health insurance and thus catered for their healthcare costs out- of- pocket. 
The total direct cost of managing diabetes was Kshs. 16,349 per capita per month. 
The World Health Organization estimated the total health expenditure per capita per 
year in Kenya in 2014 was USD 169 (WHO, 2019), which represents about a tenth of 
the amount spent by diabetes patients in this study. People with chronic illness such 
·as diabetes use healthcare services more than those without chronic illnesses. A case 
control study done in Mali in 2017 compared the healthcani costs between diabetic 
and non- diabetic patients over a ninety- day pe1iod. The results showed that while 
_non- diabetic patients spent a total of USD 88.7 on health care, diabetic patieiifs spent 
USD 314.8 which was almost four times higher than that incurred by non- diabetic 
patients (Bennudez-tamayo et al., 2017). A similar study done in the United States in 
1999 estimated the mmual medical cost of non- diabetic patients to be USD 1,991 
while that of diabetic patients was USD 4,248 (J . B. Brown & Nichols, 1999). In 
Morocco, the per capita direct cost of diabetes in 2013 was between USD 259 and 
USD 830 per year, representing 1.75 to 5~6 times the per capita health expenditure-
usn 148 (Boutayeb et al., 2013). The ratio between the cost in this study and 
Kenya's total health expenditure provided by WHO is higher than in the studies done 
in Mali, USA and Morocco possibly because persons diagnosed with diabetes in 
Kenya are much sicker and need more services and medication than their 
counterparts in the aforementioned countries. 
Direct healthcare costs comprised the largest p01iion of total direct costs- Kshs. 
13,261, which represented 81.1% of the total. Direct non- health care costs stood at 
Kshs. 3,088 per capita per month, which represented 18.9% of the total. The high 
proportion of direct health care costs as a percentage of total direct costs calls for an 
elaborate analysis into the modes of treatment used and a deeper emphasis on 
diabetes prevention. The cost of hospitalization comp1ised the largest share of this 
costs at 51.1 %. It is worth noting that the respondents in this study did not have 
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diabetes- related complications which are bound to escalate this cost further. Hospital 
admissions are the largest single item of diabetes expenditure in most countries, 
whereby hyperglycemic emergencies account for the largest share of reasons for 
admission (Pepper et al., 2014). In this study, of the respondents who had been 
admitted between January 2018 and November 2018, 61.5% of them were admitted 
due to hyperglycemia. In 2014, a survey of medical admissions to a South African 
secondary level hospital ' s high care unit over a twelve month period indicated that 
25.6% of admissions were due to hyperglycemic emergencies (Smit, Burch, & 
Willcox, 2007). The high frequency of hyperglycemia-related admissions is despite 
the fact that they are potentially preventable with prompt diabetes diagnosis, 
effective patient and health professional education. The cost of drugs was found to be 
highest among patients on both oral drugs and insulin, Kshs. 948 per month per 
person. Those on insulin only spent Kshs. 673 while those on oral drugs only spent 
Kshs. 474 per month. All over Afric_a patients struggle to afford insulin despite 
government subsidies (Azevedo & All a, 2008). The high cost of insulin __ coupled with 
perennial shortages are considered the major reasons for poor control of blood sugar 
levels in diabetic patients (Azevedo & Alia, 2008). In Kenya, insulin is subsidized by 
the government and sold to patients at a lower price. However, these subsidized 
supplies often run out or are not well distributed, forcing patients to purchase insulin 
fl-om private entities where the price is much more than at public facilities. High 
morbidity and mortality are likely to result from such inaccessibility, more so for 
patients who have an absolute deficiency of insulin. 
Of direct non- healthcare costs, the cost of hiring an extra housekeeper accounted for 
the largest proportion at 41.2%. This could be attributed to the higher prevalence of 
diabetes among older individuals who may not be able to handle all household chores 
on their own. This is coupled by the fact that majority of the population in Nyeri 
lives in the rural areas where chores are more physically demanding than they are in 
urban areas. 40.5% of direct non- healthcare costs went into making changes in the 
diet of the diabetic individuals. Proper nutrition is a cornerstone of diabetes 
management without which diabetes often becomes uncontrolled in tenns of blood 
glucose levels. Given the high of cost of healthcare in relation to income, 51.8% of 
the respondents who were not on a diabetes specific diet cited financial constraints as 
the reason for not adhering to the recommended nutlitional regimen while 21.4% 
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cited lack of knowledge on what diabetes- specific diet comprised of. This lack of 
compliance to a diabetes- specific diet places them at a risk of developing 
uncontrolled diabetes which over time leads to organ damage that is characte1istic of 
diabetes complications. A lot of focus needs to be placed on patient education in 
tenns of proper nutrition to prevent or delay the onset of these complications. 
While not all the respondents had been hospitalized, almost all had to pay for drugs 
and investigations. Lab investigations and drugs are essential patis of any disease 
management which should be common to chronic illnesses such as diabetes. The 
most frequently prescribed laboratory test was random blood glucose which was 
done on every clinic visit and is usually used as a screening tool for diabetes. 
According to a study done in Kenya in 2018 on the cost and affordability of 
screemng, diagnosis and treatment of NCDs, screening costs were generally 
inexpensive with many tests available for about USD 4 (Subramanian et al. , 2018). 
However, the diagnostic procedures for follow- up of abnormal screening results 
were substantially higher (Subramanian et al. , 2018). The payinents required to 
undergo many diagnostic tests speCifically those related to cancer and diabetes are 
beyond the reach of the average Kenyan, as the annual household expenditure per 
adult is about USD 413 (Subramanian et al., 20 18). Price data for the investigations 
was obtained from the study hospital. However, the respondents cited that they 
frequently sourced these investigations from private facilities due to frequent stock-
outs at the study hospital and other government facilities. It was difficult to obtain 
these prices as there were multiple points of care that respondents accessed these 
services. However, payments for tests are consistently lower in public- sector than in 
private- sector facilities. 
The health insurance information presented in this study shows that most 
respondents, 69.9%, were not covered and therefore had to use savings or borrow 
funds to pay for healthcare services. The Kenya Demographic Health Survey 
(KDHS) in 2014 estimated that only 17.1% of households reported to be in some 
fonn of pre- payment health scheme. Additionally, the Association of Kenya Insurers 
(AKI) 2014 annual repmi showed that about 88.4% of households with health 
insurance are covered through NHIF. Social protection, one of the main priorities for 
the Kenyan government, is outlined in the National Social Protection Policy 2011 
and is also a major goal towards realizing universal health coverage for the country 
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(Mwai, 2017). Cost of care remains a barrier to healthcare utilization as 44% of 
Kenyans who fell ill but never sought treatment cited it as the reason (Wamai, 2009). 
This is likely to bring about undesirable outcomes for those with chronic illnesses 
such as diabetes which requires prompt care to avoid or delay onset of complications. 
The average wage in Kenya is Kshs. 6,498 per month (Reuters, 2013). Moreover, 
46% of Kenyans live below the poverty line (UNICEF, 2018). This study estimated 
the total direct costs of diabetes to be Kshs. 16,349 which presents a big disparity 
between healthcare cost and income level. This may imply that individuals are either 
forced to sell off property or boiTow money to cater for healthcare costs. The effect 
of this is loss of valuable household assets and increase in debt level which may 
affect access to basic needs such as food, healthcare and education. It is wm1h noting 
that patients who adhered to a diabetes- specific diet spent less in tenns of total direct 
costs than those who did not adhere to a diabetes- specific diet- Kshs. 15,649 and 
Kshs. 17,836 respectively. This is likely due to the need for more medication, tests 
and regular follow- up in the latter group. It is however iro-nical that about half of 
patients not on a diabetes- specific diet cited financial constraints as the reason for 
not complying to the diet yet they generally spent more on healthcare than those who 
complied to a diabetes- specific diet. Coping mechanisms adopted by patients to 
contain cost such as non- adherence to the recommended lifestyle have a detrimental 
effect on their health and raise the risk .of developing complications in the long tenn 
which are much more expensive to treat than the primary disease. Unemployment 
level in Nyeri County is 17.5% and the dependence rate stands at 51% of the total 
population (NyeriCountyGovemment, 2018). 38.6% of the respondents in this study 
were unemployed and were more likely to face further impoverishment due to 
healthcare expenditure incurred in managing diabetes. The Kenya Demographic 
Health Survey 2014 estimated that 65% of women were employed all year round and 
28% were employed on a seasonal basis (KDHS, 2014). The individuals employed 
on a seasonal basis are similarly vulnerable to spiraling into poverty due to the 
unstable flow of income. Moreover, the cost of treatment and productivity losses 
stunt economic growth and negatively impact on the realization of the vision 2030 
targets and other national development targets. 
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
There is need to realize the devastating economic effects of diabetes on patients and 
families in Kenya and in low income countries in general. Without fonnal finai1cial 
suppmi to the affected families, they continue to bear the full burden of costs and at 
times result to coping mechanisms that have detrimental effects to their health and 
well- being in general. 
The UHC program which is about to be rolled out to all counties in the country in the 
2019/ 2020 financial year will help cushion cost of healthcare in public health 
facilities. This will hopefully enable patients to adhere to treatment regimen that have 
previously placed a financial strain on them and thus lead to better health outcome~. 
However, given the chronic nature of diabetes · and other non- communicable 
diseases, the cost of managing the illness has the potential of taking a large share of 
the allocated funds and may compromise funding of_ other health programs. 
Additionally, the high cost incurred by government in providing free healthcare 
services may become unattainable and as such require introduction of mechanisms to · 
raise revenue such as increase in taxes given donor funding is not always sustainable. 
This may put a further strain on Kenyans, 46% of whom live below the poverty line. 
Knowledge on the actual cost of diabetes on patients will help the government realize 
the money that can be potentially be saved when prevention of the illness is achieved 
in the population. The UHC program only caters for patients attending government 
facilities, leaving out those in faith- based and private facilities. The cost of care in 
these facilities is higher than in government and thus the need to encourage 
enrollment to health insurance schemes to protect the patients against out- of- pocket 
expenditure. 
The government of Kenya, through the Ministry of Health should encourage rigorous 
screening of the population for diabetes to ensure diabetes is diagnosed early and put 
under prompt and appropriate management. Early diagnosis and follow- up may lead 
to a reduction in healthcare costs as patients are identitied before onset of 
complications whose onset can be prevented entirely or delayed. A campaign to 
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educate diabetic patients on the ways to manage diabetes, importance of compliance 
to treatment and infonnation on diabetes complications should be instituted. With 
education and awareness, a positive attitude may develop and equip patients to battle 
with diabetes and its complications. Training of medical personnel on diabetes 
management is also critical to ensure high compliance rates among patients and 
identification of those at risk of developing complications. 
All vital drugs and tests should be made available always times in public facilities to 
reduce the incidence of seeking these c01mnodities at private facilities whose cost is 
beyond the reach of many patients, especially those with no health insurance. 
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APPENDICES 
APPENDIX 1: QUESTIONNAIRE 
I am a student of Masters of Business Administration in Healthcare Management at 
Strathmore University. I am conducing a research which aims to detem1ine the cost 
of illness of diabetes among patients attending level four and five facilities in Nyeri 
Town Sub County. This research is purely for academic purposes. I assure you-that 
all the information provided in this survey will be kept anonymous and confidential. 
Please provide honest responses. Your co-operation in this regard IS highly 
appreciated. 

















4. Highest education attained 
No formal education 
Primary 
Secondary 





















5. Current work status 
Unemployed () 
Employed () 
6. If unemployed. how do you earn income? 
Support from family members () 
Pension () 
Farming () 
Other businesses () 
SECTION 2: DIRECT COST OF DIABETES 
1. When were you diagnosed with diabetes? 
What type? 
How long have you- been attending clinic? 
( ) 0-3 years ( ) 4-6 years 
2. In the past one year, how many times have you attended diabetic outpatient 
clinic? 
() 1-5 () -10 () 15-20 ()over 20 
3. How much did you spend on oral drugs for diabetes in a month? 
() 0-1000 () 1001-2000 () 2001-3000 () 3001-4000 () 4001 -5000 
()over 5000 
4. How much did you spend on insulin and syringes in a month? 
() 0-1000 () 1001-2000 () 2001-3000 () 3001 -4000 () 4001-5000 
()over 5000 
5. How much did you spend on outpatient consultation in a month? 
() 0-1000 () 1001-2000 () 2001-3000 () 3001-4000 () 4001-5000 
()over 5000 
6. For what reasons were you hospitalized in the past one year7 
7. How much did you spend on hospitalization within that period? 
() 0-5,000 () 5001-10,000 () 10001-15000 () 15001-20000 () 20001-
25000 ()over 25000 
8. How much did you spend on insurance premium per month? 
() 0-1,000 () 1,001-2000 () 2001-3000 () 3001-4000 () 4001-5000 
()over 5000 
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9. How much do you spend on transport per clinic visit? 
() 0-500 () 501-1000 () 1001-1500 () 1501-2000 () 2001-3000 
()over 3000 
10. Do you maintain a diabetes- specific diet? If no, why are you not on a 
diabetes- specific diet? If yes, what does it comp1ise of? Is it different from 
what the rest of your family/ people you live with eat? If yes, how much more 
do you think you spend per week on the special elements of your diet? 
11 . How much do you spend to hire an extra housekeeper in a month? 
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APPENDIX 2: PARTICIPANT INFORMATION SHEET AND CONSENT 
FORM 
COST OF DIABETES DISEASE AMONG PATIENTS AT A LEVEL FOUR 
FACILITY IN NYERI TOWN SUB COUNTY 
SECTION 1: INFORMATION SHEET 
Investigator: Lucy Wamuyu Githua 
Institutional affiliation: Strathmore University Business School 
SECTION 2: THE STUDY 
2.1: Purpose of the study 
This study is an academic research in partial fulfillment towards Masters of Business 
Administration in Healthcare Management at Strathmore University Business 
School. 
2.2: Do I have to take part? 
No. Taking part in this study is voluntary. You are free to opt out of this study at any 
time without giving any reasons. If you decide to take pmi, you will be asked a series 
of questions form a questi01maire to get infonnation on your demographics and cost 
of managing diabetes. If you are unable to answer all questions successfully the first 
time, you will be requested to sit through a second session. 
2.3 Who is eligible to take part in this study? 
Patients who have lived with diabetes for up to five years and have attended diabetes 
outpatient clinic between January 2018 and November 2018. This study will target 
83 willing patients. 
2.4: Who is not eligible to take place in this study? 
Participants under the age of eighteen without a parent or guardian accompanying 
them at the time of study. 
Patients who have lived with diabetes for more than five years 
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Patients who have not attended diabetes outpatient clinic between January 2018 and 
November 2018. 
2.5: What will taking part in this study involve me? 
You will be approached and requested to take part in the study after which you will 
be requested to sign an infonned consent fonn and taken through a questionnaire 
after you fully understand the purpose of this study. 
2.6: Are there any dangers or risks in taking part in this study? 
No, there are no risks. All your infonnation will be held in utmost confidentiality and 
will not be shared with any unauthorized persons. 
2. 7: Are there any benefits of taking part in this study? 
The infonnation you provide will be used to inspire establishment of more robust 
diabetes screening programs and provide comprehensive patient education on 
diabetes prevention and management. 
2.8: What will happen to me if I refuse to take part in this study? 
Participation in this study is voluntary. You have the free will to decline participation 
in the study at any time. 
2.9: Who will have access to my information during this research? 
All your infonnation will be kept confidential. All study records will be safely stored 
in locked cabinets. Only persons closely concerned with this study will have access 
to your infonnation. 
2.10: Will there be any compensation for taking part in this study? 
No, there will not. 
2.11: Who can I contact in case I have further questions? 
You can contact me, Lucy Wamuyu Githua at Mt. Kenya Sub County Hospital, by 
email wamuyug@gmail.com or by phone number 07267 44421. You can also contact 
my supervisor, Dr. Ben Ngoye, at the Strathmore Business School, Nairobi or by 
email BN goye@strathmore.edu. 
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In case you want to contact an independent person anything about this research 
please contact: 
The Secretary- Strathmore University Institutional Ethics Review Board, P.O. BOX 
59857, 00200, Nairobi. Email : ethicsreview@strathmore.edu, Telephone number: 
+254703034375 
I, have had the study explained to me. I have understood all that has been explained 
to me, read and all my questions were answered satisfactorily. I understand that I am 
free to change my mind at any stage. 
Please tick the boxes that apply to you: 
Participation in the research study 
o I AGREE to take part in this research 
o I DO NOT AGREE to take part in this research 
Storage of information on the completed questionnaire 
o I AGREE to have my completed questionnaire stored for future data analysis 
o I DO NOT AGREE to have my complete questionnaire stored for future data 
analysis 
Participant's Signature: Date 
Participant's Name: Time 
I, Lucy Wamuyu Githua, certify that I have followed the SOP for this study and have 
explained the study infonnation to the study participant named above, and that s/he 
has understood the nature and purpose of the study and consents to the participation 
in the study. S/he has been given opportunity to ask questions which have been 
answered satisfactorily. 
Investigator's Signature: Date 
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Investigator's Name: Time 
Lucy \Vamuyu Githua 
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Thyroid function test 
Urinalysis 
Full hemogram 
Urea, creatinine and electrolytes 
HBA1c 


























APPENDIX 4: TIME SCHEDULE 
ACTIVITY WEEKS 
WK 1 WK2 WK3 WK4 WKS 
Piloting 






Corrections and submissions 
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APPENDIX 5: BUDGET ESTIMATES 
ITEM 
A) Cost of proposal development 
Stationery, printing and photocopies 
Telephone and travelling expenses 
Subtotal 
B) Cost ofData Collection and Analysis 
Research assistants- 2 
SPSS data processing 
Local transp011 costs 
Communication 
Subtotal 
C) Compilation and production of final document 
Printing 
Binding 5 copies @ Kshs. 600 
Subtotal 
Grand total 
55 
KSHS. 
5,000 
3,000 
8,000 
30,000 
25,000 
31000 
3,000 
61 ,000 
5,000 
. 3,000 
8,000 
77,000 
